Business Wire

CO-TECHSTARS

20.4.2022 14:02:25 CEST | Business Wire | Press release

Share
Techstars Appoints Chief Human Capital Officer, Aparna Ramaswamy & Chief Capital Formation Officer, Kimberly Smith

Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs, announces two strategic and operational leaders who will join the global management team effective immediately. Aparna Ramaswamy will serve as the new Chief Human Capital Officer and Kimberly Smith has been appointed to the newly formed role as Chief Capital Formation Officer, both positions report to CEO, Maëlle Gavet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005309/en/

“The best capital - whether human or financial - will pave the way for Techstars in its ambition to become the largest pre-seed investor," said Gavet. "These two deeply talented and experienced operational leaders will help Techstars continue its growth worldwide for our proven and scalable investment business."

As the new Chief Human Capital Officer, Ramaswamy has experience across a diverse portfolio of global businesses and industries/sectors including financial services, oil and gas, security, aviation, and public education. She has a recognized track record of shaping change through a strategic approach of aligning people and culture to enable businesses to scale and solve complex problems. In her most recent role as Chief Human Capital Officer for Success Academy Charter Schools in New York City, she introduced an innovative two-year leadership fellows program (Robertson Leadership Fellows) to accelerate and build the school leadership pipeline at scale and also created and led the first Inclusion Council and DEI commitments for a network of 47 public charter schools serving 20,000 children across four NYC boroughs. With Techstars’ recent announcement , launching nine diverse-led accelerators programs in partnership with J.P. Morgan, Ramaswamy’s experience in building and leading DE&I related initiatives at scale will be invaluable to the organization.

Prior to her most recent leadership role with Success Academy Charter Schools, Ramaswamy served as Co-Head of Human Resources at Bridgewater Associates and before that, spent 14 years at General Electric (GE) in progressively larger global Human Resources leadership roles across multiple businesses and industries. Based in Stamford, Connecticut, she plans to bring to Techstars her broad and varied range of global experience in talent acquisition, leadership capacity building, talent management, and total rewards, to reinforce operational excellence and deliver on Techstars’ key strategic objectives.

Ramaswamy received a Bachelor of Arts in Sociology and Psychology from St. Xavier’s College in Mumbai, India, a Master of Arts in Sociology from the University of Mumbai, India, and a Master of Business Administration from the University of Michigan Ross School of Business. In her free time, she serves on the American India Foundation Tri-State Board and is a member of the Vitalize VC Angels investment community, and the Chief Network.

Named as Techstars’ first Chief Capital Formation Officer, Smith joined the company in September 2021 and immediately began making an impact through her influence with prospective and existing investors and Limited Partners (LPs). She was integral in helping the organization close the Advancing Cities fund last month.

Based in New York City, she will be responsible for Tecshstars’ fundraising and investor relations while cultivating relationships with current and future investors - both traditional institutional LPs as well as individuals and strategic investors. Smith has spent her career raising money in the investment management sector and before joining Techstars, spent 15+ years with Owl Creek Asset Management, a NY-based event driven hedge fund, where she was a Partner and responsible for raising and retaining billions of investor capital. She has also held leadership positions in Investor Relations and Marketing at Davidson Kempner, traded coffee and sugar in the Global Futures group at ABN AMRO and got her start in finance working at Ziff Brothers.

Smith received her Bachelor of Arts from Middlebury College and her Masters of Business Administration from Fordham University. She is also the Chair of both the Board of Trustees and the Investment Committee at the Ethical Culture Fieldston School in New York City.

Following four other executive appointments within the last year, Techstars is taking bold and ambitious steps toward bringing together an industry team of leaders focused on building and growing a world-class investment business at scale.

About Techstars

The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 3,000 companies with a combined market cap of more than $172B. www.techstars.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye